Prostate Cancer Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH7 | Last Updated On: Jun 30 2022 | Available Formats

> Global Prostate Cancer Market Expected to reach at a high CAGR of 9% during the forecast period 2022-2029: DataM Intelligence

Global Prostate Cancer Market is segmented By Therapy Type (Hormone therapy, Chemotherapy, Immunotherapy, Radiation, Focal therapies, Cryosurgery, High-intensity focused ultrasound), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Prostate Cancer Market Share Growth Drivers Insights 2022

The global prostate cancer market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 9% during the forecast period (2022-2029). When cells in the prostate gland begin to grow out of control, prostate cancer develops. The prostate gland is only found in men. It produces some of the fluid found in sperm.

Report Key Highlights:

  1. New technologies in diagnostic testing are expected to boost the global prostate cancer market growth.
  2. The prostate cancer market is segmented into Therapy Type and End User.
  3. The hormone therapy segment is expected to dominate the prostate cancer market growth
  4. Growing research and developments and increasing occurrences of prostate cancer are major driving factors for the growth of the global prostate cancer market
  5. The main reasons for North American prostate cancer market control are the increasing occurrences and the huge deaths of prostate cancer in the USA
  6. The Asia Pacific offers lucrative opportunities for significant companies in the prostate cancer treatment market
  7. The rest the of regions, Latin America, the Middle East and Africa regions are anticipated to produce the utmost growth rate over the period of forecast 2022-2029

Market Dynamics

The factors influencing the global prostate cancer market are the increasing research and development and the growing prevalence of prostate cancer.

The increasing research and development is expected to drive the market growth

More information on the genetic changes that occur as prostate cancer develops and progresses is being discovered through research. Although early-stage prostate cancer contains fewer genetic changes than other types of cancer, researchers have discovered that as prostate cancer spreads throughout the body, it accumulates more mutations. Men with metastatic prostate cancer who have certain mutations may be eligible for "basket" clinical trials of novel medicines. Participants in such studies are chosen based on the mutations detected in their cancer rather than the location of cancer in the body.

A substantial percentage of men with advanced prostate cancer who participated in the NCI-MATCH trial exhibited mutations that might be targeted with experimental medications. An immune checkpoint inhibitor is a medicine that inhibits proteins in immune cells, allowing the immune system to kill cancer cells more effectively. Pembrolizumab (Keytruda), a checkpoint inhibitor, has been approved to treat tumors with particular genetic characteristics, including prostate tumors. Pembrolizumab is also approved for any metastasized tumor with many genetic alterations. However, these characteristics are found in a small percentage of prostate tumors. Prostate cancer has mainly resisted treatment with checkpoint inhibitors and other immunotherapies, such as CAR T-cell therapy.

Many NCI-funded researchers on the National Institutes of Health campus, as well as across the United States and the world, are attempting to find more effective strategies to combat prostate cancer. Some of this study is fundamental, looking into topics like cancer's biology basis and the social variables that influence cancer risk. Some are more clinical, attempting to transform fundamental data into better patient results.

Limitations associated with the treatment are expected to hamper the market growth

Treatments for prostate cancer can have a significant impact on a person's quality of life. Erectile dysfunction, the inability to develop and maintain an erection, incontinence, or the inability to control urine flow or bowel function are also possible side effects of these medications. Furthermore, many prostate tumors progress slowly and generate no signs of complications. As a result, many patients may think of postponing cancer therapy rather than commencing it immediately. This is referred to as "active surveillance." The malignancy is continuously evaluated for symptoms of worsening during active surveillance. Treatment will begin if the cancer is confirmed to be worsening.

Industry Analysis

The global prostate cancer market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.

COVID-19 Impact Analysis

The COVID-19 epidemic has negatively influenced early diagnosis by lowering participation in screening programs and time from diagnosis to surgery/radiotherapy, which may translate into poorer prostate-cancer-specific mortality in the coming years. Patients with metastatic prostate cancer history of symptomatic COVID-19 may also experience more severe chemotherapy-related side effects. Hence, covid-19 is expected to have a negative impact on the global prostate cancer market.

Prostate Cancer Market Scope

Metrics

Details

Market CAGR

9%

Segments Covered

By Therapeutics, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Segment Analysis

Prostate cancer hormone therapy is a medication that prevents the male hormone testosterone from being created or reaching cancer cells in the prostate. The majority of prostate cancer cells rely on testosterone to increase. Prostate cancer cells die or grow more slowly due to hormone therapy. Hormone therapy for prostate cancer may include drugs or testicular removal surgery. Androgen deprivation therapy is another name for hormone therapy for prostate cancer. Prostate cancers require androgens to grow early in their development.

Hormone therapy, or treatments that lower androgen levels or block androgen activity, can slow the progression of prostate tumors that are castration sensitive, androgen-dependent, or androgen sensitive. Once they stop responding to hormone therapy, most prostate cancers become castration (or castrate) resistant. Even when androgen levels in the body are extremely low or undetectable, they continue to rise.

These tumors were previously referred to as hormone-resistant, androgen-independent, or hormone-refractory; however, these words are no longer often used because the tumors' growth is not completely independent of androgens. In fact, several novel hormone therapies are now available to treat cancers that have developed a resistance to castration. The most commonly used hormone therapies for prostate cancer and the first form of hormone therapy that most men with prostate cancer receive are treatments that suppress androgen production by the testicles.

Regional Analysis

North America region is expected to hold the largest market share in the global prostate cancer market

The growing prevalence of prostate cancer and increasing research and development is expected to drive the market growth in this region. Prostate cancer strikes roughly one out of every eight men at some point in their lives.

Prostate cancer is more common in older men and non-Hispanic Black men. Men over 65 account for around 6 out of every 10 cases, whereas men under 40 are extremely uncommon. According to the American Cancer Society, approximately 268,490 new cases of prostate cancer will be diagnosed in the United States in 2022. Prostate cancer claims the lives of approximately 34,500 men each year. Hence, the increasing prevalence of prostate cancer is expected to boost the market growth in this region.

Competitive Landscape

The global prostate cancer market is highly competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Novartis International AG, Clovis Oncology Inc., and others.

Company Profile

Novartis International AG:

Overview: Novartis International AG is a Swiss-American global pharmaceutical firm headquartered in Basel, Switzerland, and Cambridge, Massachusetts.

Product Portfolio: Adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have had androgen receptor (AR) pathway inhibition and taxane-based chemotherapy might consider PLUVICTO(lutetium Lu 177 vipivotide tetraxetan).

Key Development: On March 23rd, 2022, Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) was approved by the Food and Drug Administration for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

 

Trending Topics

Pituitary Cancer Market

Bone Cancer Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Discount Applied



25% discount offer

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest